Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder

A progress report

J. Volavka, T. B. Cooper, M. Meisner, I. Bitter, P. Czobor, J. Jaeger

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

To test the hypothesis of a ''therapeutic window,'' we have randomly assigned acutely exacerbating schizophrenic or schizoaffective patients to one of three plasma levels of haloperidol (HAL): 2-13, 13.1-24, or 24.1-35 ng/ml. Patients who did not improve after 6 weeks of this treatment were randomly assigned to one of the three haloperidol levels for another 6 weeks. The improvement was defined as at least 50 percent reduction of the Brief Psychiatric Rating Scale (BPRS) total score. The results obtained in 111 patients do not support any consistent relationship between plasma level of haloperidol and clinical improvement. Patients in the high haloperidol plasma range tended to have more side effects. These results suggest that the haloperidol doses used in clinical practice may be higher than necessary.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalPsychopharmacology Bulletin
Volume26
Issue number1
Publication statusPublished - 1990

Fingerprint

Haloperidol
Psychotic Disorders
Schizophrenia
Brief Psychiatric Rating Scale
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder : A progress report. / Volavka, J.; Cooper, T. B.; Meisner, M.; Bitter, I.; Czobor, P.; Jaeger, J.

In: Psychopharmacology Bulletin, Vol. 26, No. 1, 1990, p. 13-17.

Research output: Contribution to journalArticle

@article{1139258af32b4ef6ad618c51368f8be2,
title = "Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: A progress report",
abstract = "To test the hypothesis of a ''therapeutic window,'' we have randomly assigned acutely exacerbating schizophrenic or schizoaffective patients to one of three plasma levels of haloperidol (HAL): 2-13, 13.1-24, or 24.1-35 ng/ml. Patients who did not improve after 6 weeks of this treatment were randomly assigned to one of the three haloperidol levels for another 6 weeks. The improvement was defined as at least 50 percent reduction of the Brief Psychiatric Rating Scale (BPRS) total score. The results obtained in 111 patients do not support any consistent relationship between plasma level of haloperidol and clinical improvement. Patients in the high haloperidol plasma range tended to have more side effects. These results suggest that the haloperidol doses used in clinical practice may be higher than necessary.",
author = "J. Volavka and Cooper, {T. B.} and M. Meisner and I. Bitter and P. Czobor and J. Jaeger",
year = "1990",
language = "English",
volume = "26",
pages = "13--17",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder

T2 - A progress report

AU - Volavka, J.

AU - Cooper, T. B.

AU - Meisner, M.

AU - Bitter, I.

AU - Czobor, P.

AU - Jaeger, J.

PY - 1990

Y1 - 1990

N2 - To test the hypothesis of a ''therapeutic window,'' we have randomly assigned acutely exacerbating schizophrenic or schizoaffective patients to one of three plasma levels of haloperidol (HAL): 2-13, 13.1-24, or 24.1-35 ng/ml. Patients who did not improve after 6 weeks of this treatment were randomly assigned to one of the three haloperidol levels for another 6 weeks. The improvement was defined as at least 50 percent reduction of the Brief Psychiatric Rating Scale (BPRS) total score. The results obtained in 111 patients do not support any consistent relationship between plasma level of haloperidol and clinical improvement. Patients in the high haloperidol plasma range tended to have more side effects. These results suggest that the haloperidol doses used in clinical practice may be higher than necessary.

AB - To test the hypothesis of a ''therapeutic window,'' we have randomly assigned acutely exacerbating schizophrenic or schizoaffective patients to one of three plasma levels of haloperidol (HAL): 2-13, 13.1-24, or 24.1-35 ng/ml. Patients who did not improve after 6 weeks of this treatment were randomly assigned to one of the three haloperidol levels for another 6 weeks. The improvement was defined as at least 50 percent reduction of the Brief Psychiatric Rating Scale (BPRS) total score. The results obtained in 111 patients do not support any consistent relationship between plasma level of haloperidol and clinical improvement. Patients in the high haloperidol plasma range tended to have more side effects. These results suggest that the haloperidol doses used in clinical practice may be higher than necessary.

UR - http://www.scopus.com/inward/record.url?scp=0025042597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025042597&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 13

EP - 17

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -